<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?</h1>
  <ul>
<li>Shares of CorMedix CRMD have soared 59.7% in the year-to-date period.</li>
<li>In the past year, CorMedix shares have surged 83.3% against the industry’s 13.8% decline.</li>
<li>In 2025, CorMedix anticipates Melinta’s portfolio to generate $125 million to $135 million in revenues.</li>
<li>In the first half of 2025, DefenCath delivered $78.8 million in net revenues, reflecting a solid start to its commercial journey.</li>
<li>CorMedix has also raised its guidance for DefenCath sales to the range of $200-$215 million in 2025 compared with the previous expectation of $180-$200 million in sales.</li>
<li>market exclusivity through 2033.</li>
<li>Management now expects 2025 pro forma revenues in the $325-$350 million range, with the deal projected to be accretive to earnings per share by 2026.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/cormedix-rallies-60-ytd-indication-142700729.html">Source</a> · 2025-09-15T14:27:00+00:00</p>
</body>
</html>